ZYNE - Zynerba Pharma rises 6% on positive data from Fragile X syndrome treatment trial

• Zynerba Pharmaceuticals ( NASDAQ: ZYNE ) said on Wednesday a comprehensive data review showed its therapy, Zygel, could treat Fragile X syndrome (FXS) based on the central role the endocannabinoid system in neuronal development and function.
• The company said cannabidiol could help restore the function of the endocannabinoid system (ECS) in FXS patients according to review of data.
• Fragile X syndrome is a rare genetic developmental disability that causes both inherited intellectual disability and autism spectrum disorder.
• "These findings bolster our confidence in the design of the ongoing, confirmatory, pivotl Phase 3 RECONNECT trial," the company said.
• ( ZYNE ) is trading ~6% higher before the bell.

For further details see: